サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1339165

ブランドジェネリック市場、シェア、規模、動向、産業分析レポート：薬剤クラス別、用途別、投与経路別、流通チャネル別、地域別、セグメント別予測、2023年～2032年

Branded Generics Market Share, Size, Trends, Industry Analysis Report, By Drug Class ; By Application; By Route of Administration; By Distribution Channel; By Region, And Segment Forecasts, 2023 - 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 117 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
ブランドジェネリック市場、シェア、規模、動向、産業分析レポート：薬剤クラス別、用途別、投与経路別、流通チャネル別、地域別、セグメント別予測、2023年～2032年
出版日: 2023年07月23日
発行: Polaris Market Research
ページ情報: 英文 117 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、ブランドジェネリックの世界市場規模は2032年までに4,108億6,000万米ドルに達する見込みです。本レポートでは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

糖尿病、高血圧、がんなどの慢性疾患の増加率が医薬品需要を牽引しています。ブランドジェネリック医薬品は、高価なブランド医薬品に代わるより手頃な選択肢を提供するため、慢性疾患に悩む患者にとって一般的な選択肢となりつつあります。ジェネリック医薬品の普及もブランドジェネリック市場を牽引する要因の一つです。

ジェネリック医薬品は、品質、安全性、有効性において先発医薬品と同等であるため、医師と患者の両方により広く受け入れられるようになりました。医療費全体を削減するためにジェネリック医薬品の使用を促進する政府の取り組みも、ブランドジェネリック医薬品市場の成長を後押ししています。世界各国の政府は、医療費を削減し、患者が手頃な価格で医薬品を入手できるようにするため、ジェネリック医薬品の使用を推進しています。

感染症および非感染症の負担増は、高齢者人口の増加とともにヘルスケア産業の成長にプラスの影響を与えると予想されます。糖尿病、高血圧、肥満などの慢性疾患は世界的に蔓延しつつあり、老年人口はこれらの病気にかかりやすくなっています。

その結果、ブランドジェネリックを含むヘルスケアサービスや製品に対する需要が大幅に増加すると予想されています。NCBIの論文によると、2021年には世界全体で5億3,700万人の糖尿病患者がいるとされています。糖尿病は慢性疾患であり、継続的な治療と管理が必要です。ブランドジェネリックは、高価な先発医薬品に代わるより手頃な選択肢を提供するため、糖尿病患者にとって人気の選択肢となりつつあります。

高血圧もまた、高齢者の間で蔓延している慢性疾患です。世界保健機関（WHO）によると、高血圧は世界で10億人に影響を及ぼしており、2025年には15億人に増加すると予想されています。ブランドジェネリック医薬品は、高血圧症に手頃な価格の治療選択肢を提供し、市場における需要を牽引しています。

ブランドジェネリック市場レポートハイライト

高齢者における心疾患の増加、および低価格の代替品の入手可能性により、抗高血圧薬セグメントが最大シェアを占める

経口薬セグメントは、最小限の看護経験で経口ベースの薬剤投与が可能であり、患者の受容性が高いという利点があるため、市場シェアが大きいです。

主に新興国市場での小売薬局数の増加により、小売薬局の売上シェアが拡大すると予測される

APACは、低価格医薬品への嗜好の高まりにより、調査期間中に高い成長率を記録すると予測される

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のブランドジェネリック市場に関する洞察

  • ブランドジェネリック市場- 流通チャネルのスナップショット
  • ブランドジェネリック市場力学
    • 促進要因と機会
      • 慢性疾患の有病率の増加
      • 失効特許の増加
    • 抑制要因と課題
      • 厳格な規制政策とブランド医薬品との巨大な競合
  • PESTEL分析
  • ブランドジェネリック市場の流通チャネルの動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界のブランドジェネリック市場、薬剤クラス別

  • 主な調査結果
  • イントロダクション
  • アルキル化剤
  • 代謝拮抗物質
  • ホルモン
  • 降圧剤
  • 脂質低下薬
  • 抗うつ薬
  • 抗精神病薬
  • 抗てんかん薬
  • その他

第6章 世界のブランドジェネリック市場、用途別

  • 主な調査結果
  • イントロダクション
  • 腫瘍学
  • 心血管疾患
  • 神経疾患
  • 消化器疾患
  • 皮膚疾患
  • 急性および慢性の痛み
  • その他

第7章 世界のブランドジェネリック市場、流通チャネル別

  • 主な調査結果
  • イントロダクション
  • 局所
  • 経口
  • 非経口

第8章 世界のブランドジェネリック市場、地域別

  • 主な調査結果
  • イントロダクション
    • ブランドジェネリック市場評価、地域別、2019～2032年
  • ブランドジェネリック市場-北米
    • 北米：ブランドジェネリック市場、薬剤クラス別、2019～2032年
    • 北米：ブランドジェネリック市場、流通チャネル別、2019～2032年
    • 北米：ブランドジェネリック市場、用途別、2019～2032年
    • ブランドジェネリック市場-米国
    • ブランドジェネリック市場- カナダ
  • ブランドジェネリック市場- 欧州
    • 欧州：ブランドジェネリック市場、薬剤クラス別、2019～2032年
    • 欧州：ブランドジェネリック市場、流通チャネル別、2019～2032年
    • 欧州：ブランドジェネリック市場、用途別、2019～2032年
    • ブランドジェネリック市場- 英国
    • ブランドジェネリック市場- フランス
    • ブランドジェネリック市場- ドイツ
    • ブランドジェネリック市場- イタリア
    • ブランドジェネリック市場- スペイン
    • ブランドジェネリック市場- オランダ
    • ブランドジェネリック市場- ロシア
  • ブランドジェネリック市場- アジア太平洋
    • アジア太平洋：ブランドジェネリック市場、薬剤クラス別、2019～2032年
    • アジア太平洋：ブランドジェネリック市場、流通チャネル別、2019～2032年
    • アジア太平洋：ブランドジェネリック市場、用途別、2019～2032年
    • ブランドジェネリック市場- 中国
    • ブランドジェネリック市場- インド
    • ブランドジェネリック市場- マレーシア
    • ブランドジェネリック市場- 日本
    • ブランドジェネリック市場- インドネシア
    • ブランドジェネリック市場- 韓国
  • ブランドジェネリック市場-中東およびアフリカ
    • 中東およびアフリカ：ブランドジェネリック市場、薬剤クラス別、2019～2032年
    • 中東およびアフリカ：ブランドジェネリック市場、流通チャネル別、2019～2032年
    • 中東およびアフリカ：ブランドジェネリック市場、用途別、2019～2032年
    • ブランドジェネリック市場- サウジアラビア
    • ブランドジェネリック市場- アラブ首長国連邦
    • ブランドジェネリック市場- イスラエル
    • ブランドジェネリック市場- 南アフリカ
  • ブランドジェネリック市場-ラテンアメリカ
    • ラテンアメリカ：ブランドジェネリック市場、薬剤クラス別、2019～2032年
    • ラテンアメリカ：ブランドジェネリック市場、流通チャネル別、2019～2032年
    • ラテンアメリカ：ブランドジェネリック市場、用途別、2019～2032年
    • ブランドジェネリック市場- メキシコ
    • ブランドジェネリック市場- ブラジル
    • ブランドジェネリック市場- アルゼンチン

第9章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • Teva Pharmaceutical
  • Lupin
  • Sanofi
  • Sun Pharmaceutical Industries
  • Dr. Reddy's Laboratories
  • Endo International
  • GlaxoSmithKline
  • Pfizer
  • Apotex
  • Viatris, Inc.
図表

List of Tables

  • Table 1 Global Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 2 Global Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 3 Global Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 4 Branded Generics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 6 North America: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 7 North America: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 8 U.S.: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 9 U.S.: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 10 U.S.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 11 Canada: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 12 Canada: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 13 Canada: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 14 Europe: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 15 Europe: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 16 Europe: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 17 UK: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 18 UK: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 19 UK: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 20 France: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 21 France: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 22 France: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 23 Germany: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 24 Germany: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 25 Germany: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 26 Italy: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 27 Italy: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 28 Italy: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 29 Spain: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 30 Spain: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 31 Spain: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 35 Russia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 36 Russia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 37 Russia: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 41 China: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 42 China: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 43 China: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 44 India: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 45 India: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 46 India: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 50 Japan: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 51 Japan: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 52 Japan: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 56 South Korea: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 57 South Korea: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 58 South Korea: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 65 UAE: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 66 UAE: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 67 UAE: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 68 Israel: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 69 Israel: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 70 Israel: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 71 South Africa: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 72 South Africa: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 73 South Africa: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 74 Latin America: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 75 Latin America: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 76 Latin America: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 77 Mexico: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 78 Mexico: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 79 Mexico: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 80 Brazil: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 81 Brazil: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 82 Brazil: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 83 Argentina: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 84 Argentina: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 85 Argentina: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Branded Generics Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Application
  • Figure 7. Global Branded Generics Market, by Application, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Drug Class
  • Figure 9. Global Branded Generics Market, by Drug Class, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Branded Generics Market, by Distribution Channel, 2022 & 2032 (USD Billion)
  • Figure 12. Branded Generics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Branded Generics Market
目次
Product Code: PM3545

The global branded generics market size is expected to reach USD 410.86 billion by 2032, according to a new study by Polaris Market Research. The report "Branded Generics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Alkylating Agents, Antimetabolites, Anti-Hypertensive); By Application; By Route of Administration; By Distribution Channel; By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Increasing rates of chronic diseases such as diabetes, hypertension, and cancer are driving the demand for drugs. Branded generics are becoming a popular choice for patients suffering from chronic illnesses as they offer a more affordable alternative to expensive brand-name drugs. The widespread use of generic drugs is another factor driving the branded generics market.

Generic drugs have become more widely accepted by both physicians and patients as they are equivalent in quality, safety, and efficacy to their brand-name counterparts. Government initiatives promoting the use of generic drugs to reduce overall healthcare costs are also driving the growth of the branded generics market. Governments worldwide are promoting the use of generic drugs to lower healthcare costs and increase access to affordable medicines for patients.

Growing burden of infectious and non-infectious diseases, along with the rising geriatric population, is expected to have a positive impact on the healthcare industry's growth. Chronic diseases such as diabetes, hypertension, and obesity are becoming more prevalent worldwide, and the geriatric population is more susceptible to these diseases.

As a result, the demand for healthcare services and products, including branded generics, is expected to increase significantly. According to an NCBI article, there were 537 million patients suffering from diabetes globally in 2021. Diabetes is a chronic disease that requires ongoing medical care and management. Branded generics are becoming a popular choice for diabetic patients as they offer a more affordable alternative to expensive brand-name drugs.

Hypertension is another chronic disease that is prevalent among the geriatric population. According to the World Health Organization (WHO), hypertension impacts 1 Bn people globally, and this is expected to rise to 1.5 Bn, by 2025. Branded generics offer an affordable treatment option for hypertension, which is driving their demand in the market.

Branded Generics Market Report Highlights

Anti-hypersensitive segment accounted for the largest share, owing to rise in cardiac ailments among geriatrics, and availability of low-cost alternatives

Oral segment accounted for the larger market share, owing to the advantages of oral based drug administration with minimal nursing experience, with high accept patient acceptability

Retail pharmacy is projected to experience larger revenue share, primarily due to increase in number of retail pharmacies in the developed markets

APAC is projected to register a higher growth rate in the study period, due to increase in preference of low-cost medicines

The global players include: Teva Pharmaceutical, Lupin, Sanofi, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Endo International, GlaxoSmithKline, Pfizer, Apotex, and Viatris, Inc.

Polaris Market Research has segmented the branded generics market report based on drug class, application, route of administration, by distribution channel, and region:

Branded Generics, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • Alkylating Agents
  • Antimetabolites
  • Hormones
  • Anti-Hypertensive
  • Lipid Lowering Drugs
  • Anti-Depressants
  • Anti-Psychotics
  • Anti-Epileptics
  • Others

Branded Generics, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Oncology
  • Cardiovascular Diseases
  • Neurological Diseases
  • Gastrointestinal Diseases
  • Dermatological Diseases
  • Acute and Chronic Pain
  • Others

Branded Generics, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

  • Topical
  • Oral
  • Parenteral
  • Others

Branded Generics, Distribution Channel Industry Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Branded Generics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Distribution Channels
    • 3.2.1. Primary Distribution Channels
    • 3.2.2. Secondary Distribution Channels

4. Global Branded Generics Market Insights

  • 4.1. Branded Generics Market - Distribution Channel Snapshot
  • 4.2. Branded Generics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing prevalence rate of chronic diseases
      • 4.2.1.2. Rising number of expired patents
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Strict regulatory policies and huge competition from branded drugs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Branded Generics Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Branded Generics Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • 5.3. Alkylating Agents
    • 5.3.1. Global Branded Generics Market, by Alkylating Agents, by Region, 2019-2032 (USD Billion)
  • 5.4. Antimetabolites
    • 5.4.1. Global Branded Generics Market, by Antimetabolites, by Region, 2019-2032 (USD Billion)
  • 5.5. Hormones
    • 5.5.1. Global Branded Generics Market, by Hormones, by Region, 2019-2032 (USD Billion)
  • 5.6. Anti-Hypertensive
    • 5.6.1. Global Branded Generics Market, by Anti-Hypertensive, by Region, 2019-2032 (USD Billion)
  • 5.7. Lipid Lowering Drugs
    • 5.7.1. Global Branded Generics Market, by Lipid Lowering Drugs, by Region, 2019-2032 (USD Billion)
  • 5.8. Anti-Depressants
    • 5.8.1. Global Branded Generics Market, by Anti-Depressants, by Region, 2019-2032 (USD Billion)
  • 5.9. Anti-Psychotics
    • 5.9.1. Global Branded Generics Market, by Anti-Psychotics, by Region, 2019-2032 (USD Billion)
  • 5.10. Anti-Epileptics
    • 5.10.1. Global Branded Generics Market, by Anti-Epileptics, by Region, 2019-2032 (USD Billion)
  • 5.11. Others
    • 5.11.1. Global Branded Generics Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Branded Generics Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • 6.3. Oncology
    • 6.3.1. Global Branded Generics Market, by Oncology, by Region, 2019-2032 (USD Billion)
  • 6.4. Cardiovascular Diseases
    • 6.4.1. Global Branded Generics Market, by Cardiovascular Diseases, by Region, 2019-2032 (USD Billion)
  • 6.5. Neurological Diseases
    • 6.5.1. Global Branded Generics Market, by Neurological Diseases, by Region, 2019-2032 (USD Billion)
  • 6.6. Gastrointestinal Diseases
    • 6.6.1. Global Branded Generics Market, by Gastrointestinal Diseases, by Region, 2019-2032 (USD Billion)
  • 6.8. Dermatological Diseases
    • 6.8.1. Global Branded Generics Market, by Dermatological Diseases, by Region, 2019-2032 (USD Billion)
  • 6.9. Acute and Chronic Pain
    • 6.9.1. Global Branded Generics Market, by Acute and Chronic Pain, by Region, 2019-2032 (USD Billion)
  • 6.10. Others
    • 6.10.1. Global Branded Generics Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Branded Generics Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 7.3. Topical
    • 7.3.1. Global Branded Generics Market, by Topical, By Region, 2019-2032 (USD Billion)
  • 7.4. Oral
    • 7.4.1. Global Branded Generics Market, by Oral, By Region, 2019-2032 (USD Billion)
  • 7.5. Parenteral
    • 7.5.1. Global Branded Generics Market, by Parenteral, By Region, 2019-2032 (USD Billion)
  • 7.6. Oral
    • 7.6.1. Global Branded Generics Market, by Oral, By Region, 2019-2032 (USD Billion)

8. Global Branded Generics Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Branded Generics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Branded Generics Market - North America
    • 8.3.1. North America: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.3.2. North America: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.3.3. North America: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.3.4. Branded Generics Market - U.S.
      • 8.3.4.1. U.S.: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.3.5. Branded Generics Market - Canada
      • 8.3.5.1. Canada: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • 8.4. Branded Generics Market - Europe
    • 8.4.1. Europe: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.4. Branded Generics Market - UK
      • 8.4.4.1. UK: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.5. Branded Generics Market - France
      • 8.4.5.1. France: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.6. Branded Generics Market - Germany
      • 8.4.6.1. Germany: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.7. Branded Generics Market - Italy
      • 8.4.7.1. Italy: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.8. Branded Generics Market - Spain
      • 8.4.8.1. Spain: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.9. Branded Generics Market - Netherlands
      • 8.4.9.1. Netherlands: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.10. Branded Generics Market - Russia
      • 8.4.10.1. Russia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • 8.5. Branded Generics Market - Asia Pacific
    • 8.5.1. Asia Pacific: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.5.4. Branded Generics Market - China
      • 8.5.4.1. China: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.5.5. Branded Generics Market - India
      • 8.5.5.1. India: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.5.6. Branded Generics Market - Malaysia
      • 8.5.6.1. Malaysia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.5.7. Branded Generics Market - Japan
      • 8.5.7.1. Japan: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.5.8. Branded Generics Market - Indonesia
      • 8.5.8.1. Indonesia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.5.9. Branded Generics Market - South Korea
      • 8.5.9.1. South Korea: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • 8.6. Branded Generics Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.6.4. Branded Generics Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.6.5. Branded Generics Market - UAE
      • 8.6.5.1. UAE: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.6.6. Branded Generics Market - Israel
      • 8.6.6.1. Israel: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.6.7. Branded Generics Market - South Africa
      • 8.6.7.1. South Africa: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • 8.7. Branded Generics Market - Latin America
    • 8.7.1. Latin America: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.7.4. Branded Generics Market - Mexico
      • 8.7.4.1. Mexico: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.7.5. Branded Generics Market - Brazil
      • 8.7.5.1. Brazil: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.7.6. Branded Generics Market - Argentina
      • 8.7.6.1. Argentina: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Branded Generics Market, by Application, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Teva Pharmaceutical
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Drug Class Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Lupin
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Drug Class Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Sanofi
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Drug Class Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Sun Pharmaceutical Industries
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Drug Class Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Dr. Reddy's Laboratories
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Drug Class Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Endo International
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Drug Class Benchmarking
    • 10.6.4. Recent Development
  • 10.7. GlaxoSmithKline
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Drug Class Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Pfizer
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Drug Class Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Apotex
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Drug Class Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Viatris, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Drug Class Benchmarking
    • 10.10.4. Recent Development